Genesystem진시스템
363250 · KOSDAQ · ₩363250 · 진시스템
- Market cap
- ₩35B
- Enterprise value
- ₩35B
- P/E
- —
- P/B
- 3.0×
- Dividend yield
- 0.0%
- ROE
- −87.1%
- Net margin
- −1,018.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−43.3% from the high
₩2,850Today: ₩3,975 – ₩4,120₩7,260
Returns
- 1W+0.5%
- 1M−1.9%
- 3M−9.5%
- 6M−25.1%
- YTD+0.5%
- 1Y−34.8%
- Volume today
- 3,797
- 0.6× the 20-day average
- Traded today
- ₩15M
- Listed shares
- 8,508,382
- EPS (12 months)
- −₩1,208
- Earnings yield −29.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- MomentumFlat-1% over the last month; the price is above its 20-day average.
- News impactSome4 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Genesystem stock overview
Genesystem (진시스템, KRX: 363250) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops, manufactures and services molecular diagnostic solutions, with main product lines covering molecular diagnostic systems, biochips, test kits and reagents. Its shares closed at ₩4,120 on Oct 27, 2026, up 2.74% on the day, giving it a market value of ₩35B.
Key facts
- Market cap
- ₩35B
- Sector
- Medical & precision devices
- Latest price change
- +2.74%
- As of
- Oct 27, 2026
- Main business
- The company develops, manufactures and services molecular diagnostic solutions, with main product lines covering molecular diagnostic systems, biochips, test kits and reagents.
Quick answers about Genesystem
- What does Genesystem do?
- The company develops, manufactures and services molecular diagnostic solutions, with main product lines covering molecular diagnostic systems, biochips, test kits and reagents. Its portable PCR instruments, including the GENECHECKER line, are designed for on-site testing, and it sells products directly or through distributors, with OEM customers supplied under supply contracts. Its products are sold in Korea and overseas, with exports accounting for about 45% of revenue.
- What is the market cap of Genesystem?
- The market capitalisation of Genesystem was ₩35B at the close on Oct 27, 2026.
- Who are the largest shareholders of Genesystem?
- According to the latest official filings, the largest reported holders are H Investment Partnership (16.81%, as of Apr 7, 2026); Seo Yu-jin (12.85%, as of Apr 7, 2026); Mirae Asset Global Investors (4.83%, as of Jan 6, 2026).
- When is the next earnings report from Genesystem?
- Korean companies rarely announce results dates in advance. Based on when Genesystem filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Genesystem?
- Yes. The National Pension Service held 4.02% of Genesystem shares as of Jan 2, 2026.
Company profile
The company develops, manufactures and services molecular diagnostic solutions, with main product lines covering molecular diagnostic systems, biochips, test kits and reagents. Its portable PCR instruments, including the GENECHECKER line, are designed for on-site testing, and it sells products directly or through distributors, with OEM customers supplied under supply contracts. Its products are sold in Korea and overseas, with exports accounting for about 45% of revenue.
Written by AI from the company's latest annual report.
- Korean name
- 진시스템
- Themes
- Medical devices
- CEO
- 서유진, 박성영
- Founded
- Mar 2010
- Listed
- May 2021
- Listed shares
- 8,508,382
- Fiscal year ends
- Month 12
- Website
- www.genesystem.co.kr
Similar companies
- TSE131290 · ₩2.9T₩260,000+7.88%
- Kctech281820 · ₩1.8T₩91,900+6.37%
- Classys214150 · ₩1.7T₩26,500−2.57%
- Park Systems140860 · ₩1.6T₩225,500+1.12%
- Curiox Biosystems445680 · ₩1.1T₩62,300+6.13%
- DI003160 · ₩1.1T₩37,800+4.71%
- Seers458870 · ₩1T₩26,300−5.57%
- LivsMed491000 · ₩937B₩37,100+1.50%
Recent filings
See all- Amended attachment: Merger decisionOct 16, 2026
- Occurrence of Dissolution Event (Major Management Matters of Subsidiary)Oct 15, 2026
- Merger decisionOct 15, 2026
- Merger decisionOct 15, 2026
- Material Matters Report (Decision on Transfer of Tangible Assets)Oct 12, 2026
Titles in Korean until English translations are added.
Also known as: Genesystem / 진시스템 / 363250 / KRX:363250
Source: KRX statistical information